Trading of Neurotrope was halted at 01:00 PM EST due to "LULD pause".This company has been marked as potentially delisted and may not be actively trading. Neurotrope (NTRP) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsShort InterestTrendsBuy This Stock NTRP vs. MODV, YGMZ, MOND, BKNG, EXPE, XPO, MMYT, GATX, GXO, and VRRMShould you be buying Neurotrope stock or one of its competitors? The main competitors of Neurotrope include ModivCare (MODV), MingZhu Logistics (YGMZ), Mondee (MOND), Booking (BKNG), Expedia Group (EXPE), XPO (XPO), MakeMyTrip (MMYT), GATX (GATX), GXO Logistics (GXO), and Verra Mobility (VRRM). These companies are all part of the "transportation services" industry. Neurotrope vs. ModivCare MingZhu Logistics Mondee Booking Expedia Group XPO MakeMyTrip GATX GXO Logistics Verra Mobility Neurotrope (NASDAQ:NTRP) and ModivCare (NASDAQ:MODV) are both small-cap consumer discretionary companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Do analysts prefer NTRP or MODV? Neurotrope currently has a consensus target price of $5.00, suggesting a potential upside of 195.86%. ModivCare has a consensus target price of $8.38, suggesting a potential upside of 473.63%. Given ModivCare's stronger consensus rating and higher probable upside, analysts clearly believe ModivCare is more favorable than Neurotrope.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurotrope 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ModivCare 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor NTRP or MODV? In the previous week, Neurotrope and Neurotrope both had 1 articles in the media. ModivCare's average media sentiment score of 0.47 beat Neurotrope's score of 0.00 indicating that ModivCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurotrope 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ModivCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in NTRP or MODV? Neurotrope received 157 more outperform votes than ModivCare when rated by MarketBeat users. Likewise, 63.16% of users gave Neurotrope an outperform vote while only 48.94% of users gave ModivCare an outperform vote. CompanyUnderperformOutperformNeurotropeOutperform Votes18063.16% Underperform Votes10536.84% ModivCareOutperform Votes2348.94% Underperform Votes2451.06% Do insiders and institutionals hold more shares of NTRP or MODV? 3.8% of Neurotrope shares are owned by institutional investors. 8.4% of Neurotrope shares are owned by insiders. Comparatively, 1.2% of ModivCare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, NTRP or MODV? Neurotrope has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, ModivCare has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Is NTRP or MODV more profitable? Neurotrope has a net margin of 0.00% compared to ModivCare's net margin of -6.57%. ModivCare's return on equity of 26.14% beat Neurotrope's return on equity.Company Net Margins Return on Equity Return on Assets NeurotropeN/A -806.36% -112.57% ModivCare -6.57%26.14%1.08% Which has preferable earnings and valuation, NTRP or MODV? Neurotrope has higher earnings, but lower revenue than ModivCare. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurotrope$630K4.27N/AN/AN/AModivCare$2.79B0.01-$204.46M-$14.15-0.10 SummaryNeurotrope and ModivCare tied by winning 7 of the 14 factors compared between the two stocks. Get Neurotrope News Delivered to You Automatically Sign up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTRP vs. The Competition Export to ExcelMetricNeurotropeTransportation services IndustryDiscretionary SectorNASDAQ ExchangeMarket Cap$2.69M$12.32B$7.66B$8.04BDividend YieldN/A4.90%3.39%4.22%P/E RatioN/A17.1316.7318.83Price / Sales4.272.687.51106.72Price / CashN/A25.8516.4234.62Price / Book0.513.354.554.33Net IncomeN/A$467.60M$261.05M$247.97M Neurotrope Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTRPNeurotrope1.3101 of 5 stars$1.69-9.6%$5.00+195.9%-24.1%$2.69M$630,000.000.005Trading HaltedHigh Trading VolumeMODVModivCare3.9828 of 5 stars$1.00+1.4%$8.38+737.6%-93.8%$14.34M$2.79B-0.0820,200YGMZMingZhu Logistics1.26 of 5 stars$1.03+2.0%N/A-61.3%$4.92M$55.81M0.0080Short Interest ↓News CoveragePositive NewsHigh Trading VolumeMONDMondee1.4719 of 5 starsN/A$3.63+∞N/A$87,000.00$232.97M0.001,226Upcoming EarningsBKNGBooking4.0993 of 5 stars$4,437.63-3.0%$5,278.66+19.0%+49.4%$145.62B$23.74B25.6524,300Earnings ReportAnalyst ForecastAnalyst RevisionEXPEExpedia Group4.9722 of 5 stars$146.67-3.0%$190.18+29.7%+18.6%$18.90B$13.69B16.2116,500Upcoming EarningsNews CoverageXPOXPO4.3013 of 5 stars$93.93-2.9%$139.89+48.9%-2.5%$11.06B$8.07B29.0823,000Earnings ReportAnalyst ForecastGap UpMMYTMakeMyTrip2.2402 of 5 stars$100.38-2.8%$122.50+22.0%+59.3%$11.02B$935.76M54.553,340Short Interest ↓Positive NewsGATXGATX2.9419 of 5 stars$146.03-0.7%$161.00+10.3%+16.5%$5.21B$1.59B18.791,900Dividend AnnouncementGXOGXO Logistics3.5721 of 5 stars$33.21-1.9%$54.93+65.4%-26.6%$3.97B$11.71B29.65135,000Upcoming EarningsVRRMVerra Mobility2.3011 of 5 stars$20.99-1.5%$26.67+27.0%-8.4%$3.35B$879.21M34.981,430Upcoming EarningsPositive News Related Companies and Tools Related Companies ModivCare Alternatives MingZhu Logistics Alternatives Mondee Alternatives Booking Alternatives Expedia Group Alternatives XPO Alternatives MakeMyTrip Alternatives GATX Alternatives GXO Logistics Alternatives Verra Mobility Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTRP) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurotrope With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NTRP Stock Free NTRP Stock Alerts